A Look At Stevanato Group’s (NYSE:STVN) Valuation After Its Recent Share Price Rebound

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

How Stevanato Group stock has been trading recently

Stevanato Group (NYSE:STVN) has drawn fresh attention after a sharp recent move, with the stock up 4.3% on the day and gaining 16.9% over the past week.

Those short term shifts sit alongside a month return of 37.8% and a past 3 months gain of 34.3%, set against a negative year to date return of 7.7% and a 1 year total return decline of 12.6%.

See our latest analysis for Stevanato Group.

At a share price of $19.0, Stevanato Group’s recent strength, with a 1 month share price return of 37.8%, contrasts with a weaker 1 year total shareholder return of a 12.6% decline. This suggests momentum has turned positive after a tougher stretch.

If this rebound has you looking for other healthcare exposure linked to technology, it could be an interesting moment to scan a wider field of potential opportunities via 32 healthcare AI stocks

With Stevanato Group trading at $19.0 and data pointing to a possible discount to some valuation estimates, the key question for you is simple: is this a genuine value opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 23.1% Undervalued

Stevanato Group’s most followed narrative places fair value at $24.72, above the last close at $19.00. Under that view, today’s share price is framed as a discount to future earnings potential.

The growing prevalence of biologics and novel drug classes (including GLP-1s, mAbs, and biosimilars) is driving robust, increasing demand for Stevanato's high-value containment and delivery solutions, evidenced by high growth rates in these product lines and strong order pipelines from major pharma clients, which supports ongoing revenue expansion. Secular shifts toward self-administration and personalized medicine are accelerating demand for specialized, integrated drug delivery devices (e.g., auto-injectors, pen injectors, and dual/chamber syringes), areas where Stevanato is expanding capacity and capability, suggesting greater future revenue mix from higher-margin solutions and sustained margin expansion.

Read the complete narrative.

Curious what growth path and margin lift would need to materialize to support that higher price tag? The narrative leans on rising earnings power, a richer product mix, and a premium profit multiple tied to biologics and self-administration trends. The full set of assumptions is where the story really takes shape.

Result: Fair Value of $24.72 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Story Continues

However, this hinges on execution, with risks related to rising capital and operating costs at new facilities, as well as customer concentration in a few large biopharma accounts.

Find out about the key risks to this Stevanato Group narrative.

Next Steps

If this mix of optimism and caution rings true for you, take a closer look at the key positives backing the thesis and weigh them against your own expectations with 3 key rewards

Looking for more investment ideas?

Do not stop with a single stock. Use the Simply Wall St Screener to uncover other ideas that fit your goals before the market moves without you.

Target potential mispricings by scanning 44 high quality undervalued stocks that pair quality fundamentals with attractive entry points. Strengthen your income focus by reviewing 12 dividend fortresses that offer substantial yields backed by underlying fundamentals. Sleep easier by filtering for 74 resilient stocks with low risk scores that score well on resilience and financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include STVN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments